Agios Pharmaceuticals stock surged over 14% after the FDA accepted its supplemental New Drug Application for mitapivat for sickle cell disease with Priority Review status and set a decision goal date of November 1. While the drug failed to meet its primary endpoint for reducing sickle cell pain crises, the FDA's accelerated approval pathway indicates confidence in the submitted data. Full traditional approval remains contingent on a confirmatory Phase 3 trial expected next year.

Agios presented detailed Phase 3 RISE UP trial results for mitapivat, an oral pyruvate kinase activator for sickle cell disease. The drug demonstrated statistically significant hemoglobin response improvement versus placebo with rapid onset and durable effects, clinically meaningful reduction in transfusion burden (41.1% relative reduction in patients requiring transfusions), and improvements in pain crises, fatigue, and quality of life measures among hemoglobin responders. Mitapivat was well-tolerated with a safety profile consistent with previous trials.

Agios Pharmaceuticals announced it will not advance tebapivat, a pyruvate kinase activator, in lower-risk myelodysplastic syndromes (LR-MDS) after Phase 2b trial results failed to meet predefined efficacy thresholds. While the drug was well-tolerated with no safety concerns, clinical benefit was insufficient in patient populations tested. The company will continue development of tebapivat in sickle cell disease with Phase 2 data expected in the second half of 2026.

Agios Pharmaceuticals stock surged 13% after reporting Q1 2026 earnings that beat analyst expectations. The company's lead drug mitapivat, marketed as Aqvesme and Pyrukynd, generated $20.7 million in revenue, up from $8.7 million year-over-year. The company plans to submit a supplemental FDA application for mitapivat in sickle cell disease treatment this quarter.

Agios Pharmaceuticals stock plummeted 23% after Novo Nordisk announced superior trial results for its sickle cell treatment etavopivat compared to Agios' mitapavit. Novo's drug met both primary endpoints and demonstrated statistically significant reduction in vaso-occlusive crises, while Agios' mitapavit failed to meet its primary endpoint. With Novo planning FDA approval filing in late 2026, Agios faces a longer and more uncertain path to market approval, significantly diminishing its mitapavit's commercial potential.

The alpha thalassemia market is expected to expand significantly through 2036, driven by rising prevalence and advancements in diagnostics and gene therapies. Key players Agios Pharmaceuticals and Novo Nordisk are leading development efforts with emerging drugs like PYRUKYND and etavopivat progressing through clinical trials, though no gene therapies are currently approved for the condition.

Agios Pharmaceuticals announced it will host a conference call on April 29, 2026, to report Q1 2026 financial results. The company is advancing mitapivat toward potential U.S. accelerated approval in sickle cell disease following a pre-sNDA meeting with the FDA, and has received approval for PYRUKYND (mitapivat) for adults with thalassemia in the United Arab Emirates.

Agios Pharmaceuticals stock surged over 21% after the FDA approved an accelerated approval pathway for its mitapivat drug to treat sickle cell disease. The company can now conduct an abbreviated confirmatory trial before seeking full FDA approval within months. While the drug shows promise in a market expected to grow from $4B to $14B by 2034, investors should note Agios remains unprofitable with significant losses despite recent gains.

Viswanadhan Krishnan, Chief Corporate Development and Strategy Officer at Agios Pharmaceuticals, sold 2,959 shares worth ~$82,000 on March 5, 2026. However, this was a routine, pre-planned tax-withholding sale triggered by RSU vesting, not a discretionary sale indicating loss of confidence. Krishnan retains 16,200 unvested RSUs and recently received fresh compensation grants, signaling growing equity stake. Agios' lead drug PYRUKYND showed strong 86% revenue growth, and the company announced plans to pursue FDA accelerated approval for sickle cell disease.

Agios Pharmaceuticals announced it will host a conference call and live webcast on February 12, 2026, at 8:00 a.m. ET to report its fourth quarter and full year 2025 financial results and business highlights. The company also outlined its 2026 strategic priorities and key milestones to accelerate rare disease portfolio growth.

Agios Pharmaceuticals shares surged over 18% following FDA approval of AQVESME (mitapivat) for treating alpha- and beta-thalassemia. The company priced the drug at $425,000 annually in the U.S. and projects $1 billion in global peak-year sales across thalassemia and pyruvate kinase deficiency indications. Management's positive conference call and expansion plans drove investor enthusiasm.

The FDA has approved Agios Pharmaceuticals' AQVESME (mitapivat), an oral pyruvate kinase activator, for treating anemia in adults with alpha- or beta-thalassemia. AQVESME is the only FDA-approved medicine for both non-transfusion-dependent and transfusion-dependent forms of the disease. The approval is based on Phase 3 ENERGIZE and ENERGIZE-T trials showing significant improvements in hemoglobin levels, fatigue, and transfusion burden. The drug will be available in late January 2026 under a REMS program due to hepatocellular injury risks observed in clinical trials.